Effects of curcumin on glycemic control and lipid profile in prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis

Nalinee Poolsup, Naeti Suksomboon, Putu Dian Marani Kurnianta, Kulchalee Deawjaroen, Nalinee Poolsup, Naeti Suksomboon, Putu Dian Marani Kurnianta, Kulchalee Deawjaroen

Abstract

Scope: Studies have demonstrated inconsistent effects of curcumin on glycemic outcomes and lipid parameters in patients with prediabetes and type 2 diabetes mellitus (T2DM). This study aimed to assess the effect of curcumin on glycemic control and lipid profile in prediabetes and T2DM.

Methods and results: A systematic search of randomized controlled trials (RCTs) was conducted from inception to June 2018 in electronic sources including AMED, ANZCTR, BioMed Central, CENTRAL, CINAHL, ClinicalTrials.gov, Expanded Academic Index, Google Scholar, ISRCTN, LILACS, MEDLINE, NCCIH, Science Direct, Scopus, Web of Science, and WHO ICTRP. Hand search was also performed. Of the total 486 records, four trials (N = 508) and eight trials (N = 646) were eligible for the meta-analysis of individuals with prediabetes and T2DM, respectively. Curcumin significantly reduced glycosylated hemoglobin (HbA1c) in prediabetics (MD: -0.9%, 95% CI: -1.7 to -0.1%, p = 0.03). Furthermore, T2DM subjects gained favorable reduction in both HbA1c (MD: -0.5%, 95% CI: -1.0 to -0.0%, p = 0.04) and fasting plasma glucose (MD: -11.7 mg/dL, 95% CI: -22.1 to -1.3 mg/dL, p = 0.03). Tendency of lipid profile improvement was also observed.

Conclusion: Our findings may encourage curcumin supplementation based on its meaningful effect on glycemic control and positive trend on lipid outcomes in prediabetes and T2DM.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. PRISMA flow diagram of the…
Fig 1. PRISMA flow diagram of the study selection.
Fig 2. Risk of bias summary for…
Fig 2. Risk of bias summary for each included study.
(+) low risk of bias, (-) high risk of bias, (?) unclear risk of bias.
Fig 3. Meta-analysis of glycemic outcomes in…
Fig 3. Meta-analysis of glycemic outcomes in prediabetes and type 2 diabetes mellitus.

References

    1. World Health Organization. Global report on diabetes. 2016 [cited 2018 Sep 30]. Available from: .
    1. International Diabetes Federation. IDF diabetes atlas. Brussels, Belgium: International Diabetes Federation; 2015.
    1. American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care. 2017; 40(1):S1–135.
    1. Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Barnighausen T, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 2017; 5(6):423–30. 10.1016/S2213-8587(17)30097-9
    1. Demmers A, Korthout H, van Etten-Jamaludin FS, Kortekaas F, Maaskant JM. Effects of medicinal food plants on impaired glucose tolerance: A systematic review of randomized controlled trials. Diabetes Res Clin Pract. 2017; 131:91–106. 10.1016/j.diabres.2017.05.024
    1. Suksomboon N, Poolsup N, Boonkaew S, Suthisisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J Ethnopharmacol. 2011; 137(3):1328–33. 10.1016/j.jep.2011.07.059
    1. Ng QX, Koh SSH, Chan HW, Ho CYX. Clinical use of curcumin in depression: A meta-analysis. J Am Med Dir Assoc. 2017; 18(6):503–508. 10.1016/j.jamda.2016.12.071
    1. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem. 2005; 53(4):959–63. 10.1021/jf0483873
    1. Kim HS, Hwang YC, Koo SH, Park KS, Lee MS, Kim KW, et al. PPAR-gamma activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic beta-cells. PloS One. 2013; 8(1):e50128 10.1371/journal.pone.0050128
    1. Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014; 28(12):1770–7. 10.1002/ptr.5197
    1. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res. 2016; 30:1540–8. 10.1002/ptr.5659
    1. Adab Z, Eghtesadi S, Vafa M, Heydari I, Shojaei A, Haqqani H, et al. Effect of turmeric on body measurement indices, glycemic condition, and lipid profile in hyperlipidemic patients with type 2 diabetes. Iran J Nutr Sci Food Technol. 2013; 8(3):217–27.
    1. Na LX, Li Y, Pan HZ, Zhou XL, Sun DJ, Meng M, et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res. 2013; 57(9):1569–77. 10.1002/mnfr.201200131
    1. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: A randomized controlled trial. J Nutr Biochem. 2014; 25(2):144–50. 10.1016/j.jnutbio.2013.09.013
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097 10.1371/journal.pmed.1000097
    1. Hirst JA, Steven RJ, Farmer AJ. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change. PLoS One. 2014; 9(3):e92458 10.1371/journal.pone.0092458
    1. Higgins JPT, Altman DG. (Eds.), Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons, Chichester (UK) 2008.
    1. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 2005; 5:13 10.1186/1471-2288-5-13
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557–60. 10.1136/bmj.327.7414.557
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629–34.
    1. Wickenberg J, Ingemansson SL, Hlebowicz J. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J. 2010; 9:43 10.1186/1475-2891-9-43
    1. Sengupta K, Mishra AT, Rao MK, Sarma KV, Krishnaraju AV, Trimurtulu G. Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study. Lipids Health Dis. 2012; 11(1):122–31.
    1. Nakayama H, Tsuge N, Sawada H, Masamura N, Yamada S, Satomi S, et al. A single consumption of curry improved postprandial endothelial function in healthy male subjects: a randomized, controlled crossover trial. Nutr J. 2014; 13(1):67.
    1. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendia LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol. 2016; 68(3):223–9. 10.1097/FJC.0000000000000406
    1. Cicero AFG, Fogacci F, Morbini M, Colletti A, Bove M, Veronesi M, et al. Nutraceutical effects on glucose and lipid metabolism in patients with impaired fasting glucose: A pilot, double-blind, placebo-controlled, randomized clinical trial on a combined product. High Blood Press Cardiovasc Prev. 2017; 24(3):283–8. 10.1007/s40292-017-0206-3
    1. Grant SJ, Chang DH, Liu J, Wong V, Kiat H, Bensoussan A. Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial. BMC Complement Altern Med. 2013; 13:104 10.1186/1472-6882-13-104
    1. Kurian GA, Manjusha V, Nair SS, Varghese T, Padikkala J. Short-term effect of g-400, polyherbal formulation in the management of hyperglycemia and hyperlipidemia conditions in patients with type 2 diabetes mellitus. Nutrition. 2014; 30(10):1158–64. 10.1016/j.nut.2014.02.026
    1. Mahajan S, Chauhan P, Subramani SK, Anand A, Borole D, Goswamy H, et al. Evaluation of “GSPF kwath”: a gymnema sylvestre-containing polyherbal formulation for the treatment of human type 2 diabetes mellitus. Eur J Integr Med. 2015; 7(3):303–11.
    1. Mani UV, Iyer U, Mani I, Desikachar HSR. Long-term effect of cereal-pulse mix (diabetic mix) supplementation on serum lipid profile in non-insulin-dependent diabetes mellitus patients. J Nutr Environ Med. 1997; 7(3):163–8.
    1. Rotman-Pikielny P, Ness-Abramof R, Charach G, Roitman A, Zissin R, Levy Y. Efficacy and safety of the dietary supplement DBCare(R) in patients with type 2 diabetes mellitus and inadequate glycemic control. J Am Coll Nutr. 2014; 33(1):55–62. 10.1080/07315724.2014.870008
    1. Setiawan AS, Yulinah E, Adnyana IK, Permana H, Sudjana P. Antidiabetic effect of garlic extract (Allium sativum Linn.) and curcumin extract (Curcuma domestica Val.) combination compared to glibenclamide in type 2 diabetes meliitus. MKB. 2011; 43(1):26–34.
    1. Sukandar EY, Permana H, Adnyana IK, Sigit JI, Ilyas RA, Hasimun P, et al. Clinical study of turmeric (Curcuma longa L.) and Garlic (Allium sativum L.) extracts as antihyperglycemic and antihyperlipidemic agent in type-2 diabetes-dyslipidemia patients. Int J Pharm. 2010; 6(4):438–45.
    1. Sukandar EY, Sudjana P, Adnyana IK, Setiawan AS, Yuniarni U. Recent study of turmeric in combination with garlic as antidiabetic agent. Procedia Chem. 2014; 13(Supplement C):44–56.
    1. Banerji S, Banerjee S. A formulation of grape seed, Indian gooseberry, turmeric and fenugreek helps controlling type 2 diabetes mellitus in advanced-stage patients. Eur J Integr Med. 2016; 8(5):645–53.
    1. Yang H, Xu W, Zhou Z, Liu J, Li X, Chen L, et al. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. Exp Clin Endocrinol Diabetes. 2015; 123(06):360–7.
    1. Hodai H, Adibian M, Sohrab G. Effects of curcumin supplementation on BMI and blood pressure in patients with type 2 diabetes. Abstract presented at The World Congress on Clinical Trials in Diabetes. 30 Nov-1 Dec; Berlin, Germany; 2016. p. OC51.
    1. Lee MS, Wahlqvist ML, Chou YC, Fang WH, Lee JT, Kuan JC, et al. Turmeric improves post-prandial working memory in pre-diabetes independent of insulin. Asia Pac J Clin Nutr. 2014; 23(4):581–91. 10.6133/apjcn.2014.23.4.24
    1. Panahi Y, Hosseini MS, Khalili N, Naimi E, Soflaei SS, Majeed M, et al. Effects of supplementation with curcumin on serum adipokine concentrations: a randomized controlled trial. Nutrition. 2016; 32(10):1116–22. 10.1016/j.nut.2016.03.018
    1. Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, et al. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology. 2017; 25(1):25–31. 10.1007/s10787-016-0301-4
    1. Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Majeed M, et al. Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial. Complement Ther Med. 2017; 33:1–5. 10.1016/j.ctim.2017.05.006
    1. Steigerwalt R, Nebbioso M, Appendino G, Belcaro G, Ciammaichella G, Cornelli U, et al. Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med. 2012; 54(4):11.
    1. Neerati P, Devde R, Gangi AK. Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type 2 diabetes mellitus. Phytother Res. 2014; 28(12):1796–800. 10.1002/ptr.5201
    1. Selvi NMK, Sridhar MG, Swaminathan RP, Sripradha R. Efficacy of turmeric as adjuvant therapy in type 2 diabetic patients. Indian J Clin Biochem. 2015; 30(2):180–6. 10.1007/s12291-014-0436-2
    1. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012; 35(11):2121–7. 10.2337/dc12-0116
    1. Amin F, Islam N, Anila N, Gilani AH. Clinical efficacy of the co-administration of turmeric and black seeds (Kalongi) in metabolic syndrome—a double blind randomized controlled trial—TAK-MetS trial. Complement Ther Med. 2015; 23(2):165–74. 10.1016/j.ctim.2015.01.008
    1. Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs in R&D. 2008; 9(4):243–50.
    1. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol. 2011; 45(5):365–70. 10.3109/00365599.2011.585622
    1. Jiménez-Osorio AS, García-Niño WR, González-Reyes S, Álvarez-Mejía AE, Guerra-León S, Salazar-Segovia J, et al. The effect of dietary supplementation with curcumin on redox status and nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. J Ren Nutr. 2016; 26(4):237–44. 10.1053/j.jrn.2016.01.013
    1. Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour Mobarhan M, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed. 2016; 6(5):567–77.
    1. Hodaie H, Adibian M, Sohrab G, Hedayati M. The effects of curcumin supplementation on control glycemic and anthropometric indices in overweight patients with type 2 diabetes. Iran J Endocrinol Metab. 2017; 19(1):1–9.
    1. Jimenez-Osorio AS, Monroy A, Alavez S. Curcumin and insulin resistance molecular targets and clinical evidences. Biofactors. 2016; 42(6):561–80. 10.1002/biof.1302
    1. Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med. 2013; 2013:636053 10.1155/2013/636053
    1. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016; 11:95–104. 10.4137/BMI.S38440
    1. Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: Comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014; 12(5):258–68. 10.1089/met.2013.0128
    1. Parhofer KG. Interaction between glucose and lipid metabolism: More than diabetic dyslipidemia. Diabetes Metab J. 2015; 39(5):353–62. 10.4093/dmj.2015.39.5.353
    1. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007; 7(1):24–9. 10.1007/s10238-007-0121-3
    1. Calanna S, Scicali R, Di Pino A, Knop FK, Piro S, Rabuazzo AM, et al. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014; 24(6):670–6. 10.1016/j.numecd.2014.01.013
    1. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim D, Yeo WS. A meta-analysis of the clinical use of curcumin for irritable bowel syndrome (IBS). J Clin Med. 2018;7(10):298.
    1. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6(1):10.
    1. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7(7):1894–900.
    1. Page MJ, Higgins JP, Clayton G, Sterne JA, Hrobjartsson A, Savovic J. Empirical evidence of study design biases in randomized trials: Systematic review of meta-epidemiological studies. PloS One. 2016; 11(7):e0159267 10.1371/journal.pone.0159267
    1. Melo ISV, Santos AFD, Bueno NB. Curcumin or combined curcuminoids are effective in lowering the fasting blood glucose concentrations of individuals with dysglycemia: Systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2018; 128:137–44. 10.1016/j.phrs.2017.09.010
    1. Tabrizi R, Vakili S, Lankarani KB, Akbari M, Mirhosseini N, Ghayour-Mobarhan M, et al. The effects of curcumin on glycemic control and lipid profiles among patients with metabolic syndrome and related disorders: A systematic review and metaanalysis of randomized controlled trials. Curr Pharm Des. 2018; 24(27):3184–3199. 10.2174/1381612824666180828162053
    1. Sahebkar A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr. 2014;33 (3):406–14. 10.1016/j.clnu.2013.09.012
    1. Simental-Mendia LE, Pirro M, Gotto AM Jr., Banach M, Atkin SL, Majeed M, et al. Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2017:1–10.
    1. Qin S, Huang L, Gong J, Shen S, Huang J, Ren H, et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017; 16(1):68 10.1186/s12937-017-0293-y
    1. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J. 2013; 15(1):195–218. 10.1208/s12248-012-9432-8
    1. Balaji S, Chempakam B. Toxicity prediction of compounds from turmeric (Curcuma longa L). Food Chem Toxicol. 2010; 48(10):2951–9. 10.1016/j.fct.2010.07.032
    1. Kocaadam B, Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017; 57(13):2889–95. 10.1080/10408398.2015.1077195

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren